论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Fei Q, Tian X, Wu J, Zhu H, Wang Y, Peng F, Zhang W, Yin L, He X
Received 12 October 2017
Accepted for publication 22 December 2017
Published 26 February 2018 Volume 2018:11 Pages 997—1004
DOI https://doi.org/10.2147/OTT.S153942
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 4
Editor who approved publication: Dr Faris Farassati
Abstract: Extranodal
NK/T-cell lymphoma is closely associated with Epstein–Barr virus (EBV)
infection. However, the prognostic value of EBV-DNA in extranodal NK/T-cell
lymphoma remains unclear. Thus, we conducted a meta-analysis to estimate its
prognostic significance. PubMed, EMBASE, and Web of Science were used to search
for studies conducted until June 12, 2017. The pooled hazard ratio (HR) and its
95% confidence interval (CI) were calculated to evaluate the prognostic value
of pretreatment EBV-DNA on the overall survival of extranodal NK/T-cell
lymphoma. Seven eligible studies on 356 patients with extranodal NK/T-cell
lymphoma were pooled for this meta-analysis. Results suggested that the
pretreatment EBV-DNA positivity was significantly correlated with the overall
survival of extranodal NK/T-cell lymphoma (pooled HR =3.78, 95% CI: 1.52–9.40, p =0.004; heterogeneity test: I 2=52%, p =0.05). Subgroup analyses
stratified by sample type, survival analysis mode, and HR origin showed that
patients with positive pretreatment EBV-DNA had poorer prognosis than those
with negative pretreatment EBV-DNA. Moreover, the cut-off value (HR =1.66; 95%
CI: 0.73–3.73; p =0.22) might
account for the heterogeneity. No significant publication bias was observed.
Pretreatment EBV-DNA positivity can predict poor prognosis for patients with
extranodal NK/T-cell lymphoma. Future large-scale studies based on prognostic
significance of EBV-DNA for patients with extranodal NK/T-cell lymphoma are
necessary.
Keywords: extranodal natural killer/T-cell lymphoma, Epstein–Barr virus,
prognosis, meta-analysis